Natco Pharma’s marketing partner launches 10mg strength for Everolimus Tablets in US market
1st Oct 2021

Natco Pharma’s marketing partner Breckenridge Pharmaceutical, Inc., US has launched the 10 mg strength of Everolimus Tablets (generic for Afinitor) in the US market. The U.S. Food and Drug Administration previously granted final approval of this Abbreviated New Drug Application.

According to industry sales data, the 10 mg strength of Afinitor generated annual sales of $392 million during the twelve months ending July 2021. Breckenridge previously launched Everolimus tablets in 2.5 mg, 5 mg and 7.5 mg strengths during the first quarter of 2021 in the US market.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.